Objective
we will procure biomarkers and pharmaceuticals for prostate disorders. About 1 in 4 men over 55 have lower urinary tract symptoms due to benign prostatic hyperplasia, and 1 in 10 a lifetime risk of prostate cancer. Prostate disorders are a growing major socio-economic challenge because of our ageing population. We are clinicians, scientists and industrialists with complementary expertise and proven ability to collaborate. We will use prostate samples that are clinically well-defined and proprietary (DATAS) and established (suppression subtractive hybridisation, proteomics) approaches to identify changes in gene expression. We will show in clinical and model systems that these changes are important for prostate pathogenesis, and develop diagnostic/prognostics biomarkers and therapeutics for the painful and debilitating disorders of the prostate.
Fields of science
Call for proposal
Data not availableFunding Scheme
CSC - Cost-sharing contractsCoordinator
67084 STRASBOURG
France